anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Heightened spontaneous activity in sensory neurons is often reported in individuals living with chronic pain. It is possible to study this activity in rodents using electrophysiology, but these experiments require great skill and can be prone to bias. Here, we have examined whether in vivo calcium imaging with GCaMP6s can be used as an alternative approach. We show that spontaneously active calcium transients can be visualised in the fourth lumbar dorsal root ganglion (L4 DRG) through in vivo imaging in a mouse model of inflammatory pain. Application of lidocaine to the nerve, between the inflamed site and the DRG, silenced spontaneous firing and revealed the true baseline level of calcium for spontaneously active neurons. We used these data to train a machine learning algorithm to predict when a neuron is spontaneously active. We show that our algorithm is accurate in 2 different models of pain: intraplantar complete Freund adjuvant and antigen-induced arthritis, with accuracies of 90.0% ±1.2 and 85.9% ±2.1, respectively, assessed against visual inspection by an experienced observer. The algorithm can also detect neuronal activity in imaging experiments generated in a different laboratory using a different microscope configuration (accuracy = 94.0% ±2.2). We conclude that in vivo calcium imaging can be used to assess spontaneous activity in sensory neurons and provide a Google Colaboratory Notebook to allow anyone easy access to our novel analysis tool, for the assessment of spontaneous neuronal activity in their own imaging setups.
PCT No. PCT/US91/07691 Sec. 371 Date Jun. 15, 1993 Sec. 102(e) Date Jun. 15, 1993 PCT Filed Oct. 16, 1991Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.
This study will consist of 4 visits - 1 screening visit and 3 treatment visits. Screening visit will consist of a fasting chemistry panel, a health questionnaire, an Insomnia Severity Index, the Epworth Sleepiness Scale, the Pittsburgh Sleep Quality Index, the Beck Depression Inventory, the State-Trait Anxiety Inventory, and the Fatigue Severity Scale.

Ten subjects passing screening will take for 2 weeks between dinner and bedtime in a blinded and balanced order: 1. Eight ounces of cherry juice standardized to its proanthocyanidin content in the morning and 8 ounces of cherry juice standardized to its procyanidin content 1-2 hours before bedtime for 14 days; 2. A similar amount of placebo juice with the same timing for the cross-over. There will be a 2-week washout between each of the treatment periods. Subjects will be scheduled for two overnight PSGs, one at the end of each two-week treatment period. On the morning following each test the insomnia severity index and other questionnaires will be repeated. The order of the placebo juice and cherry juice will be random and balanced.
GH treatment group (n = 68): the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
Hypercapnia increases cerebral blood flow. The effects on cerebral metabolism remain incompletely understood although studies show an oxidation of cytochrome c oxidase, Complex IV of the mitochondrial respiratory chain. Systems modelling was combined with previously published non-invasive measurements of cerebral tissue oxygenation, cerebral blood flow, and cytochrome c oxidase redox state to evaluate any metabolic effects of hypercapnia. Cerebral tissue oxygen saturation and cytochrome oxidase redox state were measured with broadband near infrared spectroscopy and cerebral blood flow velocity with transcranial Doppler ultrasound. Data collected during 5-min hypercapnia in awake human volunteers were analysed using a Fick model to determine changes in brain oxygen consumption and a mathematical model of cerebral hemodynamics and metabolism (BrainSignals) to inform on mechanisms. Either a decrease in metabolic substrate supply or an increase in metabolic demand modelled the cytochrome oxidation in hypercapnia. However, only the decrease in substrate supply explained both the enzyme redox state changes and the Fick-calculated drop in brain oxygen consumption. These modelled outputs are consistent with previous reports of CO2 inhibition of mitochondrial succinate dehydrogenase and isocitrate dehydrogenase. Hypercapnia may have physiologically significant effects suppressing oxidative metabolism in humans and perturbing mitochondrial signalling pathways in health and disease.
PURPOSE:To obtain a skin medicine for external use, containing polyunsaturated fatty acids, capable of preventing the polyunsaturated fatty acids from oxidizing and stably preservable for a long period by isolating and housing a propellant in a pressure-resistant container. CONSTITUTION:The objective substance is obtained by suitably blending 0.1-60wt.% polyunsaturated fatty acid or a derivative thereof (e.g. an ester of a 1-3C lower alcohol) with normal cosmetic ingredients, preparing preferably a milky lotion or creamy composition according to a conventional method and subsequently filling a propellant (e.g. LPG) in an outer pack of a double container, and then the resultant composition in an inner pack. A constant amount of the resultant skin medicine can be taken out of the pressure-resistant container and applied to the skin for use. Thereby, the skin is prevented from drying, roughening, etc., to create young, fresh, healthy and beautiful skin.
The study will include two sleep protocols: Normal sleep and 24h sleep deprivation. The participants will be informed and will sign a consent form. Participants will then be randomly divided to begin with one of the sleep protocols. To avoid major changes in participants lifestyle, that might intervene with the basic measurements, both nights will take place within a maximum of one month and a minimum of one week for recovery between them. One week prior to each condition, participants will fill a sleep diary which will include their sleep duration to ensure that a routine sleep pattern will be maintained prior to each of the tests. Participants will be instructed not to consume alcoholic drinks or mind-altering substances for 24h prior, and during both conditions, and caffeine for 12h prior and during both conditions.

To enable normal sleep as possible, the normal sleep protocol will take place in each of the participants home. Matching environmental conditions will be kept to those of the clinic (lighting, white background) where the sleep deprivation protocol will be held. The participants will be tested using the Video Head Impulse test (vHIT) and the Computerized Dynamic Visual Acuity test (c-DVA) during both nights. The participants will be equipped with an ActiGraph watch wGT3X-BT to assure sleeping conditions.
A human ν opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat ν opiate receptor cDNA. The human ν opiate receptor (hνOR1) shares 95% amino acid identify with the rat sequence. The expressed νOR1 recognizes tested opiate drugs and opioid peptides in a sodium- and GTP- sensitive fashion with affinities virtually identical to those displayed by the rat ν opiate receptor. Effects on cyclic AMP are similar to those noted for the rat ν opiate receptor. Overlapping genomic clones spanning 50 kilobasepairs and hybridizing with the hνOR1 cDNA contains exon sequences encoding the entire open reading frame of the human ν opiate receptor are described. Analysis of hybridization to DNA prepared from human rodent hybrid cell lines and chromosomal in situ hybridization studies indicate localization to 6q24-25. An MspI polymorphism, producing a 3.7 kb band, is being used to assess this gene's involvement in neuropsychiatric disorders involving opiatergic systems.
INTRODUCTION: Granulocytic myeloid-derived suppressor cells (G-MDSCs) show fast recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) constituting the major part of peripheral blood in the early phase. Although G-MDSCs mediate immune suppression through multiple mechanisms, they may also promote inflammation under specific conditions.
METHODS: G-MDSCs were isolated from 82 patients following allo-HSCT within 90 days after allo-HSCT, and their interactions with autologous CD3+ T-cells were examined. T-cell proliferation was assessed by flow cytometry following CFSE staining, while differentiation and interferon-γ secretion were characterized using chemokine receptor profiling and ELISpot assays, respectively. NK cell cytotoxicity was evaluated through co-culture with K562 cells. An aGVHD xenogeneic model in humanized mice was employed to study the in vivo effects of human leukocytes. Furthermore, transcriptional alterations in G-MDSCs were analyzed via RNA sequencing to investigate functional transitions.
RESULTS: G-MDSCs promoted inflammation in the early-stage, by facilitating cytokine secretion and proliferation of T cells, as well as their differentiation into pro-inflammatory T helper subsets. At day 28, patients with a higher number of G-MDSCs exhibited an increased risk of developing grades II-IV aGvHD. Besides, adoptive transfer of G-MDSCs from patients at day 28 into humanized mice exacerbated aGvHD. However, at day 90, G-MDSCs led to immunosuppression, characterized by upregulated expression of indoleamine 2,3-dioxygenase gene and interleukin-10 secretion, coupled with the inhibition of T cell proliferation. Furthermore, transcriptional analysis of G-MDSCs at day 28 and day 90 revealed that 1445 genes were differentially expressed. These genes were associated with various pathways, revealing the molecular signatures of early post-transplant differentiation in G-MDSCs. In addition, genes linked to the endoplasmic reticulum stress were upregulated in patients without aGvHD. The acquisition of immunosuppressive function by G-MDSCs may depend on the activation of CXCL2 and DERL1 genes.
CONCLUSION: Our findings revealed the alteration in the immune characteristics of G-MDSCs within the first 90 days post-allo-HSCT. Moreover, the quantity of G-MDSCs at day 28 may serve as a predictive indicator for the development of aGvHD.
Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
Overlap between language and visual variants of atypical Alzheimer's disease (AD) has been reported. However, the extent, frequency of overlap, and its neuroanatomical underpinnings remain unclear. Eighty-two biomarker-confirmed AD patients who presented with either predominant language (n = 34) or visuospatial/perceptual (n = 48) deficits underwent detailed clinical examinations, MRI, and [18F]flortaucipir-PET. Subgroups were defined based on language/visual testing and patterns of volume loss and tau uptake were assessed. 28% of the language group had visual dysfunction (marked in 8%), and 47% of the visual group had language impairment (marked in 26%). Progressive involvement of the parieto-occipital and frontal lobes was noted with greater visual impairment in the language group, and greater left parieto-temporal and frontal involvement with worsening language impairment in the visual group. Only 25% of our cohort showed a pure language or visual presentation, highlighting the high frequency of syndromic overlap in atypical AD and the diagnostic challenge of categorical phenotyping.
A composition comprising artificial outer membrane vesicles (aOMVs) generated from a gram-negative bacterium is disclosed. A composition comprising extruded outer membrane vesicles (exOMVs) generated from a gram-negative bacterium is also disclosed. The gram-negative bacterium may be genetically modified for expression of a SARS-CoV-2 protein in the outer membrane. In certain embodiments, the gram-negative bacterium is not genetically modified for expression of a SARS-CoV-2 protein in the outer membrane but the composition comprises recombinant SARS-CoV-2 protein. In certain embodiments, the gram-negative bacterium is genetically modified for expression of a SARS-CoV-2 protein in the outer membrane and the composition comprises recombinant SARS-CoV-2 protein. Any immunogenic SARS-CoV-2 protein may be used. In certain embodiments, the SARS-CoV-2 protein may be a surface exposed protein. In certain embodiments, the SARS-CoV-2 protein may be a spike protein, e.g., S protein, S1 protein, S2 protein, or a fragment thereof. In certain aspects, the SARS-CoV-2 protein is a fragment of S1 protein, e.g., receptor binding domain (RBD). Methods for making the compositions and using the compositions as a vaccine for inducing an immune response against the virus are also disclosed.
The invention relates to amphipathic amino acid block copolymer and a preparation method and application thereof. The invention discloses the amphipathic amino acid block copolymer with a general formula (I) and salt thereof, wherein m is a positive integer in the range of 1 to 200; n is a positive integer in the range of 1 to 150; X is active terminal ammonia; and Y is alkali metal. The block copolymer can be prepared by performing reaction of anhydride of one amino acid and the active terminal ammonia, then performing reaction of the obtained product and anhydride of another amino acid and removing benzyl by adopting alkali hydroxide. Micelle prepared from the polymer has low critical micelle concentration, is not influenced by pH, has high stability and high drug-loading rate, can be used as a carrier of an organic medicament and waterinsoluble or insoluble and amphipathic medicaments, and is used for endovascular or intramuscular injection, oral administration and tract or external application drug administration. The preparation method is simple. The process is mature. The amphipathic amino acid block copolymer is suitable for large-scale continuous production.
Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
In a clinical study of patients with OIC a daily dose of 50 mg (twice the recommended dosage), administered over 4 weeks, was associated with an increased incidence of GI adverse reactions, such as abdominal pain, diarrhea and nausea. These adverse reactions frequently occurred within 1-2 days after dosing.

No antidote is known for naloxegol. Dialysis was noted to be ineffective as a means of elimination in a clinical study in patients with renal failure. 

If a patient on opioid therapy receives an overdose of naloxegol, the patient should be monitored closely for potential evidence of opioid withdrawal symptoms such as chills, rhinorrhea, diaphoresis or reversal of central analgesic effect. Base treatment on the degree of opioid withdrawal symptoms, including changes in blood pressure and heart rate, and on the need for analgesia.
A disinfectant composition comprises sodium p-toluenesulphonbromamide (bromamine) and a detergent. Additional ingredients include per-salts, sodium carbonate, sodium bicarbonate, Glauber's salt, sodium chloride, soluble phosphates, silicates, cellulose ethers and esters, starch, perfumes, dyestuffs, superfatting agents, abrasives and sterilizers.  The detergent may be a fatty acid salt (soap) or any synthetic foaming or wetting agent.  The compositions may be used as powders, pastes or solutions.  An example describes an aqueous composition comprising bromamine, alkali salts of fatty acids obtained by saponification of a mixture of tallow, coconut oil and olive oil, sodium carbonate, calcite, water glass, magnesium sulphate, sodium bicarbonate, sodium perborate, perfume and dyestuff. Specification 392,814 is referred to.ALSO:A disinfectant composition comprises sodium p-toluenesulphonbromamide (bromamine) and a detergent. Additional ingredients include per-salts, sodium carbonate, sodium bicarbonate, Glauber's salt, sodium chloride, soluble phosphates, silicates, cellulose ethers esters and glycollates, starch, perfumes, dyestuffs, super-fatting agents, abrasives and sterilizers.  The detergent may be a fatty acid salt (soaps) or any synthetic foaming or wetting agent.  The compositions may be used as powders, pastes or solutions.  An example describes an aqueous composition comprising bromamine, alkali salts of fatty acids derived by saponification of a mixture of tallow, coconut oil and olive oil, sodium carbonate, calcite, water glass, magnesium sulphate, sodium bicarbonate, sodium perborate, perfume and dyestuff. Specification 392,814 is referred to.
The second group of patients will be given ticagrelor initially, and after the first 30 days it will be replaced with clopidogrel, that will be given for the remaining time period (up to 12 months). Clopidogrel dosing will be modified according to the results of the aggregometry using the ADP test.
Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
Hydrocortisone Tablets, USP contain hydrocortisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract.

Hydrocortisone USP is white to practically white, odorless, crystalline powder with a melting point of about 215°C. It is very slightly soluble in water and in ether; sparingly soluble in acetone and in alcohol; slightly soluble in chloroform.

The chemical name for hydrocortisone is pregn-4-ene-3,20-dione,11,17,21-trihydroxy-,(11β)-. Its molecular weight is 362.46 and the structural formula is as outlined below.

Hydrocortisone Tablets, USP are available for oral administration in three strengths: each tablet contains either 5 mg, 10 mg, or 20 mg of hydrocortisone. Inactive ingredients: lactose, pregelatinized corn starch, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and magnesium stearate.
Caution in handling the solution must be exercised as skin reactions associated with idarubicin hydrochloride may occur. Skin accidentally exposed to idarubicin hydrochloride should be washed thoroughly with soap and water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.

Care in the administration of idarubicin hydrochloride will reduce the chance of perivenous infiltration. It may also decrease the chance of local reactions such as urticaria and erythematous streaking. During intravenous administration of idarubicin hydrochloride extravasation may occur with or without an accompanying stinging or burning sensation even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the injection or infusion should be immediately terminated and restarted in another vein. If it is known or suspected that subcutaneous extravasation has occurred, it is recommended that intermittent ice packs (1/2 hour immediately, then 1/2 hour 4 times per day for 3 days) be placed over the area of extravasation and that the affected extremity be elevated. Because of the progressive nature of extravasation reactions, the area of injection should be frequently examined and plastic surgery consultation obtained early if there is any sign of a local reaction such as pain, erythema, edema or vesication. If ulceration begins or there is severe persistent pain at the site of extravasation, early wide excision of the involved area should be considered.

Idarubicin hydrochloride should be administered slowly (over 10 to 15 minutes) into the tubing of a freely running intravenous infusion of Sodium Chloride Injection (0.9%) or 5% Dextrose Injection. The tubing should be attached to a butterfly needle or other suitable device and inserted preferably into a large vein.
FIELD: medicine. ^ SUBSTANCE: method involves injecting a drug all around perineural regions within main nerve trunks, within a projection of cervical and lumbar enlargements. Also, the drug is injected along regions corresponding to segmental innervation of malfunctioning organs and along scalp zones considering a nature of the malfunctions observed. Besides, the drug is injected all around biologically active points used for acupuncture in traditional oriental medicine in pareses and paralyses, cerebral and peripheral blood supply disturbances. As said drug, the dispersed biomaterial Alloplant is used. It is dissolved in physiologic saline or in a local anaesthetic solution in the ratio of 10-100 mg of said biomaterial per 5-15 ml of the solution. One session includes 5-20 injections. One injection contains 0.1-5 ml of the solution. The therapeutic course is 1-15 sessions. The intersession intervals are 1 day to 3-4 weeks. ^ EFFECT: method provides higher clinical effectiveness in motor-vegetative disturbances due to prescribing the drug providing stimulation of regenerative processes in nervous system, and due to using the optimal therapeutic zones and points. ^ 4 ex, 7 cl
The effect of mirtazapine on QTc interval was assessed in a clinical randomized trial with placebo and positive (moxifloxacin) controls involving 54 healthy volunteers using exposure response analysis. This trial showed a positive relationship between mirtazapine concentrations and prolongation of the QTc interval. However, the degree of QT prolongation observed with both 45 mg and 75 mg (1.67 times the maximum recommended daily dose) doses of mirtazapine was not at a level generally considered to be clinically meaningful. During postmarketing use of mirtazapine, cases of QT prolongation, Torsades de Pointes, ventricular tachycardia, and sudden death, have been reported [see Adverse Reactions (6.1, 6.2)] . The majority of reports occurred in association with overdose or in patients with other risk factors for QT prolongation, including concomitant use of QTc-prolonging medicines [see Drug Interactions (7)and Overdosage (10)] . Exercise caution when mirtazapine tablets are prescribed in patients with known cardiovascular disease or family history of QT prolongation, and in concomitant use with other drugs thought to prolong the QTc interval.
Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.